
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is attractive because its iLet continues to gain share through a differentiated, easy-to-use closed-loop insulin delivery system, and the company has already delivered year-one public-company success with financial upside and roughly 10% NRx share. The outlook is further strengthened by raised full-year revenue expectations to $124-126M, reaffirmed key operating metrics, and a pipeline that includes Mint and 3D Intelligence, which should broaden adoption and support revenue outperformance as commercialization progresses. Although Mint’s launch may temporarily shift some revenue into 2027 and pressure near-term gross margin, the larger patch-pump opportunity, expected capacity for 1.5M+ units in 2027, and a path toward profitability support a constructive long-term fundamental view.
Bears say
Beta Bionics is facing a fundamentally challenging setup because gross margin of 57.3% missed expectations as lower-margin DME supplies and stocking dynamics offset the revenue mix from the higher-margin iLet Bionic Pancreas. Regulatory execution risk is also elevated after the company withdrew its 510(k) submission for the 3D Intelligence Algorithm at the FDA’s request, pushing revised submission to mid-Q4 2026 and launch expectations to mid-2027. Beyond that, the bear case is reinforced by uncertain market share gains, potential pressure on pharmacy-channel penetration, possible CMS headwinds, and the risk that additional capital needs could dilute shareholders.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Beta Bionics Inc (BBNX) Forecast
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares